Skip to main content

Day: March 23, 2021

Tryg A/S offentliggør resultat af fortegningsemission

 MÅ IKKE OFFENTLIGGØRES, PUBLICERES ELLER UDLEVERES, HELT ELLER DELVIST, I ELLER TIL USA. MÅ IKKE OFFENTLIGGØRES, PUBLICERES ELLER UDLEVERES, DIREKTE ELLER INDIREKTE, HELT ELLER DELVIST, TIL ELLER DEN ITALIENSKE REPUBLIK, SCHWEIZ, AUSTRALIEN, CANADA, DE FORENEDE ARABISKE EMIRATER (ONSHORE), DUBAIS INTERNATIONALE FINANSCENTER, ABU DHABIS GLOBALE MARKED, SINGAPORE, JAPAN, HONGKONG, FOLKEREPUBLIKKEN KINA ELLER I NOGEN JURISDIKTION, HVOR UDLEVERING, PUBLICERING ELLER OFFENTLIGGØRELSE VILLE VÆRE ULOVLIG. DENNE MEDDELELSE UDGØR HVERKEN ELLER ER EN DEL AF OG SKAL IKKE OPFATTES SOM ET TILBUD OM AT SÆLGE ELLER EN OPFORDRING TIL TILBUD OM AT KØBE NOGEN AF DE HERI OMTALTE VÆRDIPAPIRER I NOGEN JURISDIKTION. INVESTORER BØR IKKE TEGNE, KØBE ELLER PÅ ANDEN MÅDE ERHVERVE, SÆLGE ELLER AFHÆNDE NOGEN AF DE HERI OMTALTE VÆRDIPAPIRER, BORTSET FRA I OVERENSSTEMMELSE...

Continue reading

Bilibili Announces Pricing of Global Offering

SHANGHAI, China, March 23, 2021 (GLOBE NEWSWIRE) — Bilibili Inc. (the “Company” or “Bilibili”) (Nasdaq: BILI), an iconic brand and a leading video community for young generations in China, today announced the pricing of the global offering (the “Global Offering”) of new 25,000,000 Class Z ordinary shares of the Company (the “Offer Shares” or “Shares”), which comprises an international offering (the “International Offering”) and a Hong Kong public offering (the “Hong Kong Public Offering”). The final offer price for both the International Offering and the Hong Kong Public Offering (the “Offer Price”) has been set as HK$808.00 per Offer Share. Based on the ratio of one Class Z ordinary share per Nasdaq-listed American depositary shares (the “ADSs”), the Offer Price translates to approximately US$104.06 per ADS based on an exchange...

Continue reading

Robotic Sensors Market worth USD 3.44 Billion at 9.8% CAGR; High Demand from Manufacturing & Healthcare Sectors to Propel Growth: Fortune Business Insights™

Pune, India, March 23, 2021 (GLOBE NEWSWIRE) — The global robotic sensors market is set to gain traction from the rising adoption of sensor-enabled collaborative robots by the manufacturing companies. They are trying to automate a wide range of operations, such as screw driving, quality inspection, and pick-&-place. This information is given by Fortune Business Insights™ in a new report, titled, “Robotic Sensors Market Size, Share & COVID-19 Impact Analysis, By Type (Light Sensor, Tactile Sensor, Temperature Sensor, Pressure Sensor, Navigation and Positioning Sensors, Proximity Sensor, Others), By End Use Industry (Aerospace and Defense, Automotive, Chemicals, Consumer Electronics, Energy and Utility, Food and Beverages, Healthcare, Logistics and Transportation, Manufacturing, Agriculture, Others) and Regional Forecast,...

Continue reading

LEADING EUROPEAN POS PROVIDER CHOSES WESTPAY AS SUPPLIER OF PAYMENT SOLUTIONS.

Westpay AB has signed a frame agreement with a leading European POS provider, and will be their preferred partner for payment solutions. The company provides point of sales (POS) solutions for merchants in the hospitality sector. The initial term of the frame agreement is four years, and deliveries of payment products and services is estimated to commence in Q2 2021. – This is exciting news for us at Westpay. This is one of the major players in Europe, and we are, of course, very proud to be teaming up with them. Now it´s all about execution and enable their business by adding our value. Again, we get the confirmation we are looking for that we are on track with a relevant offering powered by the right strategy, says Sten Karlsson, CEO at Westpay AB.   For additional information, please contact: Sten Karlsson, CEO Westpay ABMobile:...

Continue reading

Face recognition door lock Market to Reach USD 2,414.2 Million by 2028; Increasing Adoption of Modern Technology to Surge Demand: Fortune Business Insights™

Pune, India, March 23, 2021 (GLOBE NEWSWIRE) — The global Face recognition door lock market size is expected to gain momentum by reaching USD 2,414.2 million by 2028. Fortune Business Insights in its latest report, titled, “Face Recognition Door Lock Market, 2021-2028.”, mentions that the market stood at USD 737.6 million in 2020 and is projected to exhibit a CAGR of 16.2% between 2021 and 2028. This is attributable to the increasing adoption of advanced technologies in the development of smart security systems worldwide. Market to Exhibit 14.3% Growth in 2020 The manufacturing activities of several industries have suffered due to halted operations due to the global pandemic. Moreover, the companies are facing problems such as supply chain disruption, reduced workforce, and limited availability of resources. This has impacted the...

Continue reading

Elanders nominated for prestigious Swedish logistics award

Today, Elanders was nominated for PostNord Logistics Award *, an award where Sony Ericsson, Volvo Cars, and H&M are among the previous winners. To be recognized a year when the theme is “A dynamic supply chain – decisive when the world and customer needs change rapidly” is something that the President and CEO, Magnus Nilsson, truly appreciates: “We run a long-term effort to create better and more sustainable logistics solutions that also contribute to increased business benefits for our customers. This nomination is clear proof that we are on the right track.” The jury’s motivation reads: Through a determined transformation from a printing corporation into a global services enterprise, offering comprehensive logistics solutions with a wide range of innovative services and system solutions, the operations have evolved into a growing...

Continue reading

Elanders nominerat till prestigefullt logistikpris

Elanders har nominerats till PostNord Logistics Award, ett pris som tidigare vunnits av bland andra Boozt, Apotea, Ericsson, Volvo Cars och H&M. Att uppmärksammas när temat är ”En dynamisk supply chain – avgörande när världen och kundbehoven snabbt ändras” är något som Elanders koncernchef och vd, Magnus Nilsson verkligen uppskattar: ”Vi bedriver ett långsiktigt arbete för att skapa bättre och mer hållbara logistiklösningar som samtidigt bidrar till ökad affärsnytta för våra kunder. Den här nomineringen är ett tydligt bevis på att vi är på helt rätt väg.” Motiveringen från juryn lyder: Genom en målmedveten transformation från en tryckerikoncern till ett globalt tjänsteföretag, som erbjuder breda logistiklösningar med en lång rad innovativa tjänster och systemlösningar, har verksamheten utvecklats till en växande koncern på logistikens...

Continue reading

RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE

RECORDATI:  POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE   Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels in the majority of patients. These data provide further evidence of the benefits of Isturisa® as an effective and well-tolerated oral treatment option for patients with Cushing’s disease. Milan, 23 March 2021 – Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa® were presented on March 22 at the Endocrine Society’s Annual Meeting.  1   Results from LINC 4, the first Phase III study in patients with Cushing’s...

Continue reading

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL TRATTAMENTO DELLA MALATTIA DI CUSHING

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL TRATTAMENTO DELLA MALATTIA DI CUSHING   Risultati statisticamente significativi emersi dallo studio pivotale di fase III LINC-4 dimostrano che Isturisa® (osilodrostat) consente di ottenere una normalizzazione rapida e duratura dei livelli medi di cortisolo libero urinario nella maggior parte dei pazienti. Questi dati confermano ulteriormente i benefici di Isturisa® quale opzione terapeutica orale efficace e ben tollerata per i pazienti con malattia di Cushing.   Milano, 23 marzo 2021 – Recordati Rare Diseases annuncia che i risultati positivi dello studio di fase III LINC-4 con Isturisa® sono stati presentati il 22 marzo al congresso annuale dell’Endocrine...

Continue reading

Aktia’s Annual and Sustainability Report 2020 published

Aktia Bank PlcStock Exchange Release23 March 2021 at 10.00 a.m. Aktia’s Annual and Sustainability Report 2020 published Aktia has today published its Annual and Sustainability Report 2020. The report is available at www.aktia.com/en/annual-and-sustainability-report2020. The Annual and Sustainability Report comprises Aktia’s business review, the corporate responsibility report, the report by the Board of Directors, the financial statements for 2020, and the corporate governance report. Aktia’s non-financial report is included in the report by the Board of Directors. Aktia’s Capital and Risk Management Report 2020 and Remuneration Report 2020 for the governing bodies of Aktia Bank Plc have also been published at the same time. All documents are available on the company website www.aktia.com.The Annual and Sustainability Report,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.